Ivospemin clinical trials
Also written SBP-101.
How each study uses ivospemin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ivospemin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Sunovion Respiratory Development Inc. (4) · Panbela Therapeutics, Inc. (3)
Often tested with
Tested in the same studies.
Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Gemcitabine (1)
Studies
Open first, then newest update. How each study uses ivospemin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic CancerRecruitingPhase 2/3Panbela Therapeutics, Inc.NCT05254171Written as SBP-101How we know
- Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic CancerCompletedPhase 1Panbela Therapeutics, Inc.NCT03412799Written as SBP-101How we know
- Study of SBP-101 in Pancreatic CancerCompletedPhase 1Panbela Therapeutics, Inc.NCT02657330Written as SBP-101How we know
- A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPDCompletedPhase 2Sunovion Respiratory Development Inc.NCT02038829Written as SUN101 3 mcgHow we know
- Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPDCompletedPhase 3Sunovion Respiratory Development Inc.NCT02347761Written as SUN-101 50 mcg BID eFlow (CS) nebulizerHow we know
- Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)CompletedPhase 3Sunovion Respiratory Development Inc.NCT02347774Written as SUN-101 50 mcg BID eFlow (CS) nebulizerHow we know
- A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPDCompletedPhase 3Sunovion Respiratory Development Inc.NCT02276222Written as SUN-101 50 mcg BID eFlow (CS) nebulizerHow we know
Codes
What other systems call ivospemin · ClinicalTrials.gg INT015417
- UNII (FDA) 775S1NC70IIVOSPEMINOne source FDA
- NCI Thesaurus C184886IvospeminOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 775S1NC70I | IVOSPEMIN | One source FDA |
| NCI Thesaurus | C184886 | Ivospemin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.